Search hospitals > Oklahoma > Tulsa
St. John Health System
Claim this profileTulsa, Oklahoma 74104
Conducts research for Prostate Cancer
Conducts research for Head and Neck Cancers
Conducts research for Stroke
Conducts research for Brain Tumor
Conducts research for Coronavirus
73 reported clinical trials
6 medical researchers
Summary
St. John Health System is a medical facility located in Tulsa, Oklahoma. This center is recognized for care of Prostate Cancer, Head and Neck Cancers, Stroke, Brain Tumor, Coronavirus and other specialties. St. John Health System is involved with conducting 73 clinical trials across 90 conditions. There are 6 research doctors associated with this hospital, such as Anuj Malik, MD, Errol Gordon, MD, Nicholas Hanna, MD, and George Comas.Top PIs
Anuj Malik, MDAscension St. John3 years of reported clinical research
Studies Coronavirus
Studies COVID-19
5 reported clinical trials
8 drugs studied
Errol Gordon, MDSt. John Medical Center3 years of reported clinical research
Studies Stroke
Studies Hemorrhagic Stroke
3 reported clinical trials
5 drugs studied
Nicholas Hanna, MDSt. John's Health System7 years of reported clinical research
Studies Atrial Fibrillation
Studies Heart Disease
3 reported clinical trials
5 drugs studied
George ComasAscension St. John4 years of reported clinical research
Studies Stroke
Studies Bleeding
1 reported clinical trial
2 drugs studied
Clinical Trials running at St. John Health System
Stroke
Bleeding
Atrial Fibrillation
Hemorrhagic Stroke
Ischemia
Anticoagulation + Antiplatelet Therapy
for Post-Operative Atrial Fibrillation
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
Recruiting2 awards Phase 32 criteria
rFVIIa
for Hemorrhagic Stroke
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
Recruiting1 award Phase 34 criteria
Apixaban vs Aspirin
for Stroke Prevention in Atrial Fibrillation After Brain Bleed
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Recruiting1 award Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at St. John Health System?
St. John Health System is a medical facility located in Tulsa, Oklahoma. This center is recognized for care of Prostate Cancer, Head and Neck Cancers, Stroke, Brain Tumor, Coronavirus and other specialties. St. John Health System is involved with conducting 73 clinical trials across 90 conditions. There are 6 research doctors associated with this hospital, such as Anuj Malik, MD, Errol Gordon, MD, Nicholas Hanna, MD, and George Comas.